The Rs 3,290 crore (Rs 32.9 billion) Sun plans to sell Topamax in four strengths ranging from 25mg to 200mg, the combined market for which is estimated to be $2.5 billion. There is, of course, no litigation with the patent holder OrthoMcneill Janssen. The US market, which brings in about 40 per cent of Sun's consolidated sales and has driven revenues in the past few year could lose momentum.
In May, price growth for drugs was in negative territory at (-)1 per cent
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Even as conflicts between rival brands increase in India, industry experts find the trend encouraging.
Generic drug sales in the US, that power the business of such leading Indian drug manufacturers as Ranbaxy, Dr Reddy's, Sun Pharma, Lupin and Zydus Cadila, will face competition soon, as big US wholesalers decide to outsource their requirements from upcoming Indian manufacturers.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
More than 2 million people have been diagnosed with coronavirus across the world, and the pharmaceutical industry is pulling out all stops to find potential treatments and vaccines for the global pandemic. According to the World Health Organization, there are now more than 70 potential vaccines under evelopment, with some already in clinical trials.
As many as 15 companies across the world have lined up generic variants of Pfizer's Zoloft (Sertaline HCL), for which the exclusive six-month marketing period granted to the successful patent challenger, Teva of Israel, ends on Tuesday.
A massive pan-India inoculation drive against COVID-19 was set in process on Tuesday with more than 56 lakh doses of the Covishield vaccine flown to 13 cities across India from Pune and taken to designated national and state-level stores amid tight security.
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
Face NPPA fine for overcharging on anti-asthma drug
German Remedies seeks nod for amalgamation with Cadila Healthcare
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
This is reportedly the first time that the names recommended by a search committee have been shot down by the HRD ministry
'The government had a vaccine from January.' 'The government should have given the vaccine to all population above the age of 45, right from the start.' 'Each state has its own problems, but as far as vaccine coverage in India is concerned, there have been mistakes.'
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
'People are already sending congratulatory messages. But I have said, "Please don't until the trials are over".'
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
Since 2013, the FDA has banned around 30 Indian drug manufacturing units for various violations
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
The Ambanis are the only Indian family on the top 10 richest families list in Asia.
With India's imports exceeding exports, weak rupee does more harm than good. Analysts, however, say that rupee depriciation is positive for export-oriented sectors such as IT services, pharmaceuticals, textiles and automobiles
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Pharma was the top losing index amid worries about their earnings outlook with Lupin down over 4%
Ajit Mishra, vice president, Research, Religare Broking, answers your queries:
IndiGo Airlines signs $2.6-billion leasing and financing MoU with Industrial and Commercial Bank of China.
Nifty PSU bank index dropped nearly 2%
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances